Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Marin-Bejar O, Romero-Moya D, Rodriguez-Ubreva J, Distefano M, Lessi F, Aretini P, Liquori A, Castaño J, Kozyra E, Kotmayer L, Bueno C, Cervera J, Rodriguez-Gallego JC, Nomdedeu JF, Murillo-Sanjuán L, De Heredia CD, Pérez-Martinez A, López-Cadenas F, Martínez-Laperche C, Dorado-Herrero N, Marco FM, Prósper F, Menendez P, Valcárcel D, Ballestar E, Bödör C, Bigas A, Catalá A, Wlodarski MW, Giorgetti A. Marin-Bejar O, et al. Among authors: prosper f. Haematologica. 2023 Sep 1;108(9):2551-2557. doi: 10.3324/haematol.2022.282305. Haematologica. 2023. PMID: 36815365 Free PMC article. No abstract available.
Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.
Lasaga M, Río P, Vilas-Zornoza A, Planell N, Navarro S, Alignani D, Fernández-Varas B, Mouzo D, Zubicaray J, Pujol RM, Nicoletti E, Schwartz JD, Sevilla J, Ainciburi M, Ullate-Agote A, Surrallés J, Perona R, Sastre L, Prosper F, Gomez-Cabrero D, Bueren JA. Lasaga M, et al. Among authors: prosper f. Haematologica. 2023 Oct 1;108(10):2652-2663. doi: 10.3324/haematol.2022.282418. Haematologica. 2023. PMID: 37021532 Free PMC article.
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
Stölzel F, Fordham SE, Nandana D, Lin WY, Blair H, Elstob C, Bell HL, Mohr B, Ruhnke L, Kunadt D, Dill C, Allsop D, Piddock R, Soura EN, Park C, Fadly M, Rahman T, Alharbi A, Wobus M, Altmann H, Röllig C, Wagenführ L, Jones GL, Menne T, Jackson GH, Marr HJ, Fitzgibbon J, Onel K, Meggendorfer M, Robinson A, Bziuk Z, Bowes E, Heidenreich O, Haferlach T, Villar S, Ariceta B, Diaz RA, Altschuler SJ, Wu LF, Prosper F, Montesinos P, Martinez-Lopez J, Bornhäuser M, Allan JM. Stölzel F, et al. Among authors: prosper f. JCI Insight. 2023 Jan 24;8(2):e150368. doi: 10.1172/jci.insight.150368. JCI Insight. 2023. PMID: 36480300 Free PMC article.
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A, Herranz JM, Latasa MU, Arechederra M, Uriarte I, Pineda-Lucena A, Prosper F, Berraondo P, Alonso C, Sangro B, García Marin JJ, Martinez-Chantar ML, Ciordia S, Corrales FJ, Francalanci P, Alaggio R, Zucman-Rossi J, Indersie E, Cairo S, Domingo-Sàbat M, Zanatto L, Sancho-Bru P, Armengol C, Berasain C, Fernandez-Barrena MG, Avila MA. Clavería-Cabello A, et al. Among authors: prosper f. J Hepatol. 2023 Oct;79(4):989-1005. doi: 10.1016/j.jhep.2023.05.031. Epub 2023 Jun 10. J Hepatol. 2023. PMID: 37302584 Free article.
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma.
Oyon D, Lopez-Pascual A, Castello-Uribe B, Uriarte I, Orsi G, Llorente S, Elurbide J, Adan-Villaescusa E, Valbuena-Goiricelaya E, Irigaray-Miramon A, Latasa MU, Martinez-Perez LA, Bonetti LR, Prosper F, Ponz-Sarvise M, Vicent S, Pineda-Lucena A, Ruiz-Clavijo D, Sangro B, Larracoechea UA, Tian TV, Casadei-Gardini A, Amat I, Arechederra M, Berasain C, Urman JM, Avila MA, Fernandez-Barrena MG. Oyon D, et al. Among authors: prosper f. J Exp Clin Cancer Res. 2025 Jan 15;44(1):13. doi: 10.1186/s13046-024-03268-5. J Exp Clin Cancer Res. 2025. PMID: 39810240 Free PMC article.
First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas.
Justicia-Lirio P, Tristán-Manzano M, Maldonado-Pérez N, Barbero-Jiménez C, Cortijo-Gutiérrez M, Pavlovic K, Molina-Estevez FJ, Muñoz P, Hinckley-Boned A, Rodriguez-Madoz JR, Prosper F, Griñán-Lison C, Navarro-Marchal SA, Panisello C, Muñoz-Ballester J, González-Sierra PA, Herrera C, Marchal JA, Martín F. Justicia-Lirio P, et al. Among authors: prosper f. Mol Ther Nucleic Acids. 2024 Aug 15;35(4):102308. doi: 10.1016/j.omtn.2024.102308. eCollection 2024 Dec 10. Mol Ther Nucleic Acids. 2024. PMID: 39640015 Free PMC article.
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.
Zabaleta A, Puig N, Cedena MT, Oliver-Caldes A, Perez JJ, Moreno C, Tamariz-Amador LE, Rodriguez-Otero P, Prosper F, Gonzalez-Calle V, López-Corral L, Rey-Búa B, Puertas B, Mirás F, Sánchez-Pina JM, López-Muñoz N, Juan M, González-Navarro EA, Urbano Á, de Larrea CF, Blade J, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San Miguel JF, Paiva B. Zabaleta A, et al. Among authors: prosper f. Am J Hematol. 2025 Jan;100(1):93-102. doi: 10.1002/ajh.27526. Epub 2024 Nov 16. Am J Hematol. 2025. PMID: 39548827 Free PMC article.
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.
Exposito F, Redrado M, Serrano D, Calabuig-Fariñas S, Bao-Caamano A, Gallach S, Jantus-Lewintre E, Diaz-Lagares A, Rodriguez-Casanova A, Sandoval J, San Jose-Eneriz E, Garcia J, Redin E, Senent Y, Leon S, Pio R, Lopez R, Oyarzabal J, Pineda-Lucena A, Agirre X, Montuenga LM, Prosper F, Calvo A. Exposito F, et al. Among authors: prosper f. Cell Death Dis. 2024 Nov 2;15(11):787. doi: 10.1038/s41419-024-07156-w. Cell Death Dis. 2024. PMID: 39488528 Free PMC article.
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.
Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, Gottwald S, Rae R, Lechner S, Bayer C, Dekempe Q, Osl F, Carrié N, Kassem S, Lorenz S, Christopeit T, Carpy A, Bujotzek A, Bröske AM, Dekhtiarenko I, Attig J, Kunz L, Cremasco F, Adelfio R, Fertig G, Dengl S, Gassner C, Bormann F, Kirstenpfad C, Kraft T, Diggelmann S, Knobloch M, Hage C, Feddersen R, Heidkamp G, Pöschinger T, Mayoux M, Bernasconi L, Prosper F, Dumontet C, Martinet L, Leclair S, Xu W, Paiva B, Klein C, Umaña P. Eckmann J, et al. Among authors: prosper f. Blood. 2025 Jan 9;145(2):202-219. doi: 10.1182/blood.2024025987. Blood. 2025. PMID: 39476124 Free PMC article.
463 results